Daewoong Pharmaceutical successfully completed clinical trial of Easyef topical solution

Daewoong Pharmaceutical successfully completed clinical trial of Easyef topical solution - High cure rate for diabetic foot ulcers with excellent effectiveness and safety - Easyef topical solution ready to dominate global market with a series of export contracts with Turkey, Russia, etc Daewoong Pharmaceutical Co.,Ltd(President: Lee Jong-wook) announced on September 3 that it completed a large-scale clinical trial(3 phase) of ‘Easyef topical solution’, a drug for treating the diabetic foot ulcers, with excellent results. This clinical trial was conducted with the involvement of 9 hospitals, including Yonsei University Severance Hospital, Asan Medical Center, to verify the excellent effect and safety of Easyef topical solution(epidermal growth factor) for diabetic foot ulcer. The results of clinical trial showed that Easyef topical solution had a cure rate of 67.95% for diabetic foot ulcers and speeded up the healing. Easyef topical solution is the nation’s first new biomedicine that applies the EGF(Epidermal Growth Factor) for the first time worldwide. It incorporates innovative technology that induces and stimulates genetically engineered colon bacterium’s extracellular secretion of EGF in the same way as the EGF creation process inside human body. Daewoong Pharmaceutical already received approval for Easyef topical solution in South East Asian countries including Vietnam, Philippines, Thailand, and has inked contracts to export Easyef topical solution to 11 countries such as Turkey, Russia, CIS(Commonwealth of Independent States). Professor Lee Jin-woo, Orthopedics, Severance Hospital, who is a clinical researcher, said, “176 patients participated in this clinical trial and showed high cure rate with fast healing speed. Easyef topical solution is expected to provide a new groundbreaking treatment for diabetic foot ulcers.” Using this clinical trial as springboard, Daewoong Pharmaceutical will actively seek the export of Easyef topical solution as part of its global strategy. Diabetic foot ulcers mean the ulcers or necrosis caused by minor scar or infection with numbness or dullness which result from blood circulation problem or decline in capillary or peripheral nerve functions as the diabetes progresses. About 1-4% of the world's diabetic patients are experiencing diabetic foot ulcers, out of which 50% have their lower limbs amputated. A lower limb is lost to diabetic foot ulcers every 30 seconds somewhere across the globe. The global market for diabetic foot ulcer treatment drugs is worth KRW 100 billion. Currently, 1.5 million patients are suffering from this disease, and the number is increasing by 12% every year. In Korea, there are approximately 4.5 million diabetic patients and 10-20% of all hospitalized patients with diabetes have their lower limbs amputated.

The release as fetched from its publisher. daewoong.co.kr ↗